Anti-SARS-Cov-2 antibodies derived from 3bgf
AssigneeCentivax, Inc.
InventorsJacob Glanville, Shahrad Daraeikia, I-Chieh Wang, Sindy Andrea Liao Chan, Jean-Philippe Bürckert, Sawsan Youssef
Life of this patent
Estimating the term…
Abstract
This disclosure provides antibodies and antigen-binding fragments that are derived from 3bgf and that can be administered to an individual that is infected or suspected of being infected with a virus. Antibodies and antigen-binding fragments herein can be capable of treating or curing the virus, and which may provide protection against the virus for up to several weeks. Antibodies and antigen-binding fragments herein can be used to diagnose a SARS CoV-2 infection.
Claims21
An antibody or an antigen-binding fragment that selectively binds to a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), that comprises a variable heavy chain (VH) complementarity determining region 1 (CDR1) having an amino acid sequence of SEQ ID NO:
- 76;
- a VH CDR2 having an amino acid sequence of SEQ ID NO:
- 102;
- a VH CDR3 having an amino acid sequence of SEQ ID NO:
- 130;
- a variable light chain (VL) CDR1 having an amino acid sequence of SEQ ID NO:
- 13;
- a VL CDR2 having an amino acid sequence of SEQ ID NO:
- 31;
- and a VL CDR3 having an amino acid sequence of SEQ ID NO:
- 48.
An antibody or an antigen-binding fragment that selectively binds to a SARS-CoV-2, that comprises:
- (i) a VH CDR1 having an amino acid sequence of SEQ ID NO:
- 78, a VH CDR2 having an amino acid sequence of SEQ ID NO:
- 104, a VH CDR3 having an amino acid sequence of SEQ ID NO:
- 132, a VL CDR1 having an amino acid sequence of SEQ ID NO:
- 15, a VL CDR2 having an amino acid sequence of SEQ ID NO:
- 30, and a VL CDR3 having an amino acid sequence of SEQ ID NO:
- 50;
- (ii) a VH CDR1 having an amino acid sequence of SEQ ID NO:
- 77, a VH CDR2 having an amino acid sequence of SEQ ID NO:
- 103, a VH CDR3 having an amino acid sequence of SEQ ID NO:
- 131, a VL CDR1 having an amino acid sequence of SEQ ID NO:
- 14, a VL CDR2 having an amino acid sequence of SEQ ID NO:
- 32, and a VL CDR3 having an amino acid sequence of SEQ ID NO:
- 49;
- (iii) a VH CDR1 having an amino acid sequence of SEQ ID NO:
- 66, a VH CDR2 having an amino acid sequence of SEQ ID NO:
- 92, a VH CDR3 having an amino acid sequence of SEQ ID NO:
- 120, a VL CDR1 having an amino acid sequence of SEQ ID NO:
- 3, a VL CDR2 having an amino acid sequence of SEQ ID NO:
- 29, and a VL CDR3 having an amino acid sequence of SEQ ID NO:
- 38;
- or
- (iv) a VH CDR1 having an amino acid sequence of SEQ ID NO:
- 202, a VH CDR2 having an amino acid sequence of SEQ ID NO:
- 203, a VH CDR3 having an amino acid sequence of SEQ ID NO:
- 201, a VL CDR1 having an amino acid sequence of SEQ ID NO:
- 204, a VL CDR2 having an amino acid sequence of SEQ ID NO:
- 205, and a VL CDR3 having an amino acid sequence of SEQ ID NO:
- 206.
An antibody or an antigen-binding fragment that selectively binds to a SARS-CoV-2, that comprises a VH chain having an amino acid sequence of SEQ ID NO:
- 155 and a VL chain having an amino acid sequence of SEQ ID NO:
- 179.
Dependencies are inferred from the claim text.